Elligo Joins Efforts To Expand COVID-19 Risk Screening, Testing
Elligo Health Research, a healthcare-enabling research organization, is working with Verily to support the Project Baseline COVID-19 Program. The program is a collaboration with the California Governor’s office, federal, state and local public health authorities, to expand COVID-19 risk screening and testing. Elligo is one of the few companies to project-manage and staff drive-by COVID-19 test sites with three initial sample-collection sites that launched Monday, March 16 in San Mateo County and Santa Clara County. Additional locations are expected in the coming weeks.
Elligo is also providing a full spectrum of solutions to help manage COVID-19 testing efforts on-site and off-site, including access to staff and partnerships with national labs to support needs once samples are collected; site-specific recommendations on workflow, standard operating procedures, and protocols; and a support team for current medical staff, among other services.
For more, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
